Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.
Yongjun Wang, Shuya Li, Yuesong Pan...
https://pubmed.ncbi.nlm.nih.gov/36774935/Actively Recruiting
Led by Yongjun Wang · Updated on 2026-10-22
1440
Participants Needed
5
Research Sites
21 weeks
Total Duration
Researchers are investigating the best approach to treat acute ischemic stroke caused by large vessel occlusion LVO, a leading cause of disability. Mechanical thrombectomy MT is the current standard treatment, but the role of intravenous thrombolysis before MT is unclear. This phase 3 randomized trial evaluates different thrombolysis strategies using tenecteplase or reteplase compared with direct MT alone in adults presenting within 4.5 hours of stroke onset with confirmed anterior circulation LVO. Participants will be randomly assigned to one of three groups tenecteplase plus MT, reteplase plus MT, or direct MT without thrombolysis. Tenecteplase is given as a single intravenous bolus dose of 0.25 mgkg, while reteplase is administered as two 18 mg bolus injections separated by 30 minutes. Mechanical thrombectomy is performed according to standard practice. The study aims to determine if bridging thrombolysis improves functional independence at 90 days after treatment, with further comparison between the two thrombolytic agents if superiority is found. Throughout the study, participants will be assessed for functional outcomes, neurological improvement, reperfusion success, quality of life, and safety measures up to 90 days after randomization. Assessments include imaging, clinical evaluations, and monitoring for complications such as bleeding or mortality. The primary outcome is achieving functional independence, defined by a modified Rankin Scale score of 0 to 2 at 90 days. The total study duration extends to the final follow-up at 90 days post-treatment.
CONDITIONS
Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events
Y
Yongjun Wang, MD
B
Bowei Zhang, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Yongjun Wang
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - Up to 4.5 hours from symptom onset
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single treatment within 4.5 hours of stroke onset
Participants receive either tenecteplase or reteplase as intravenous thrombolysis followed by mechanical thrombectomy, or mechanical thrombectomy alone according to standard practice.
1 visit (in-person)
Duration - 90 days post-treatment
Participants are monitored and assessed for functional outcomes, neurological improvement, reperfusion success, safety, and quality of life up to 90 days after treatment.
Regular follow-up visits and assessments
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Yongjun Wang, Shuya Li, Yuesong Pan...
https://pubmed.ncbi.nlm.nih.gov/36774935/Charles B Majoie, Fabiano Cavalcante, Jan Gralla...
https://pubmed.ncbi.nlm.nih.gov/37640037/Shuya Li, Hong-Qiu Gu, Hao Li...
https://pubmed.ncbi.nlm.nih.gov/38884332/Bruce C V Campbell, Peter J Mitchell, Leonid Churilov...
https://pubmed.ncbi.nlm.nih.gov/29694815/Natalie E LeCouffe, Manon Kappelhof, Kilian M Treurniet...
https://pubmed.ncbi.nlm.nih.gov/34758251/Kentaro Suzuki, Yuji Matsumaru, Masataka Takeuchi...
https://pubmed.ncbi.nlm.nih.gov/33464334/Wenjie Zi, Zhongming Qiu, Fengli Li...
https://pubmed.ncbi.nlm.nih.gov/33464335/Bruce C V Campbell, Peter J Mitchell, Timothy J Kleinig...
https://pubmed.ncbi.nlm.nih.gov/25671797/Peter J Mitchell, Bernard Yan, Leonid Churilov...
https://pubmed.ncbi.nlm.nih.gov/35810757/Olvert A Berkhemer, Puck S S Fransen, Debbie Beumer...
https://pubmed.ncbi.nlm.nih.gov/25517348/Yongjun Wang
Lead Sponsor